1. Home
  2. RILYP vs HUMAW Comparison

RILYP vs HUMAW Comparison

Compare RILYP & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo B. Riley Financial Inc.

RILYP

B. Riley Financial Inc.

HOLD

Current Price

$12.69

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Logo Humacyte Inc. Warrant

HUMAW

Humacyte Inc. Warrant

HOLD

Current Price

$0.00

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RILYP
HUMAW
Founded
1973
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
RILYP
HUMAW
Price
$12.69
$0.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.4K
49.3K
Earning Date
01-01-0001
03-21-2025
Dividend Yield
7.03%
N/A
EPS Growth
138.49
79.37
EPS
6.47
N/A
Revenue
$967,599,000.00
$2,038,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.02
N/A
Revenue Growth
15.38
N/A
52 Week Low
$3.25
$0.00
52 Week High
$17.52
$0.40

Technical Indicators

Market Signals
Indicator
RILYP
HUMAW
Relative Strength Index (RSI) 43.67 32.00
Support Level $12.43 N/A
Resistance Level $13.75 $0.01
Average True Range (ATR) 0.36 0.00
MACD 0.03 0.00
Stochastic Oscillator 40.36 0.00

Price Performance

Historical Comparison
RILYP
HUMAW

About RILYP B. Riley Financial Inc.

BRC Group Holdings Inc is a diversified holding company offering a platform of businesses, including financial services, telecom, retail, and investments in equity, debt, and venture capital. It serves retail, corporate, capital providers, and individual customers across various business lines. The Group has seven reportable business segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, UOL, and Consumer Products. Maximum revenue is generated from the Capital Markets segment, which provides investment banking and institutional brokerage services, offers loans, trades in equity securities, and maintains an investment portfolio of public and private equities and debt securities. Geographically, the Group derives maximum revenue from its business in North America.

About HUMAW Humacyte Inc. Warrant

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: